Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Bullish +65

Charles River Laboratories stock trades near a yearly high as targets rise

Analyst upgrade Earnings report Guidance raised AI-generated analysis

📈 Charles River Laboratories stock traded at USD 294.59, just 2.88% below its 52-week high of USD 303.31.

🚀 Mizuho raised its price target from USD 264.00 to USD 295.00 while maintaining a Neutral rating.

🔼 JPMorgan upgraded its stance from Neutral to Overweight with a new price target of USD 310.00.

💰 TD Cowen increased its target to USD 325.00, signaling strong institutional interest in the stock.

📊 Robert W. Baird raised its target to USD 334.00 with an Outperform rating, implying 13.37% upside.

💸 Q2 GAAP revenue declined 2.7% year-over-year to USD 1.00 billion due to divestiture impacts.

📉 GAAP net loss widened to USD 1.5 million, or USD 0.03 per share, compared to prior periods.

✅ Non-GAAP EPS beat estimates at USD 3.02 versus the consensus of USD 2.74.

🎯 Company reaffirmed 2026 organic revenue growth guidance between 0% and 1%.

📈 Charles River raised non-GAAP EPS guidance for 2026 to a range of USD 11.15-11.45.

🌱 Long-term target set for 5% to 7% organic revenue growth through the 2027-2030 period.

💡 Company expects to generate over USD 300 million in cumulative savings from 2027 through 2030.

📉 DSA revenue fell 1.9% to USD 606.5 million, though organic DSA revenue rose 0.2%.

Bullish Signals
  • Major analyst upgrades drove stock price near yearly highs, with Baird setting a target of USD 334.00 implying 13.37% upside.
  • Non-GAAP EPS of USD 3.02 beat the consensus estimate of USD 2.74 despite GAAP losses from divestitures.
  • Company raised non-GAAP EPS guidance for 2026 to USD 11.15-11.45, showing management confidence in profitability.
  • Analysts including JPMorgan and TD Cowen increased price targets, indicating strong long-term value potential.
  • Charles River reaffirmed 2026 organic revenue growth guidance while outlining a robust 5%-7% CAGR for 2027-2030.
Risk Factors
  • Q2 GAAP revenue fell 2.7% to USD 1.00 billion, reflecting a weak reported trend despite organic stability.
  • The company recorded a net loss of USD 1.5 million in Q2 due to a USD 63.7 million charge from divestitures.
  • DSA revenue declined 1.9% year-over-year to USD 606.5 million, indicating some weakness in the diagnostics segment.
Full Analysis
Charles River Laboratories stock traded near its yearly high on September 28, 2026, following a significant wave of analyst upgrades despite a weak reported revenue trend. Major financial institutions including Mizuho, JPMorgan, TD Cowen, and Robert W. Baird raised their price targets for the company, with Baird setting a target of USD 334.00 that implies over 13% upside from the current trading price. Q2 2026 financial results showed GAAP revenue falling 2.7% to USD 1.00 billion and a net loss of USD 1.5 million driven by divestiture charges. However, on an adjusted non-GAAP basis, EPS reached USD 3.02, which beat the consensus estimate of USD 2.74. Organic revenue remained flat at 0.1% growth, while DSA revenue declined slightly but maintained organic momentum. At its September 24 Investor Day, Charles River reaffirmed its 2026 organic revenue guidance and raised non-GAAP EPS expectations to a range of USD 11.15-11.45. The company also outlined long-term strategic goals, targeting 5% to 7% organic revenue growth for the 2027-2030 period and expecting cumulative savings exceeding USD 300 million through that timeframe. The market reaction was positive as investors appear to value the raised analyst targets and improved adjusted earnings over the short-term GAAP miss. With a market capitalization of USD 14.2 billion, the stock sits within its 52-week range but close to the top end, suggesting confidence in the company's ability to execute on its cost-saving initiatives and future growth plans.